Home・Список акций・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

280.45 0.11

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

278.27

Макс.

286.83

Ключевые показатели
By Trading Economics
Доход	62M 49M
Продажи	12M 64M
P/E Средняя по отрасли	29.524 57.366
Прибыль на акцию	2.22
Рентабельность продаж	76.159
Сотрудники	47
EBITDA	87M 72M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+25.23% upside

Дивиденды
By Acuity
Следующий отчет о доходах	5 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-267M 5.6B
Предыдущая цена открытия	280.34
Предыдущая цена закрытия	280.45

Новостные настроения

By Acuity

35%

65%

136 / 340 Рейтинг в Healthcare

Ligand Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

25 авг. 2026 г., 19:46 UTC

Ligand Pharmaceuticals Inc is trading higher, benefiting from a favorable market environment amid declining crude oil prices and lower Treasury yields.

24 авг. 2026 г., 19:56 UTC

Ligand Pharmaceuticals is trading lower during Monday's session, marking the fourth consecutive day of declines. No specific news has been identified to explain the drop.

21 авг. 2026 г., 19:36 UTC

News

Ligand Pharmaceuticals is gaining today, supported by strong long-term performance and a market capitalization of $5.76 billion.

19 авг. 2026 г., 19:11 UTC

Ligand Pharmaceuticals Inc is rising today, driven by strong momentum in the Pharmaceuticals sub-sector and unusually high market volume.

18 авг. 2026 г., 19:16 UTC

Ligand Pharmaceuticals Inc is trading lower, continuing a downward trend amid rising U.S. Treasury yields and inflation concerns related to geopolitical tensions.

17 авг. 2026 г., 20:06 UTC

Ligand Pharmaceuticals Inc is declining during Monday's session, amid broader economic concerns following a drop in U.S. retail sales for July.

14 авг. 2026 г., 19:46 UTC

News

Ligand Pharmaceuticals Inc shares are higher after Leerink analyst David Risinger initiated coverage with an Outperform rating and a price target of $330.00.

13 авг. 2026 г., 19:52 UTC

News

Ligand Pharmaceuticals Inc shares are lower amid high trading volume, as initial jobless claims rose and the Producer Price Index remained flat.

12 авг. 2026 г., 19:16 UTC

Ligand Pharmaceuticals Inc shares are higher today, reflecting strength in U.S. stocks amid gains in AI-related companies and ongoing geopolitical tensions.

11 авг. 2026 г., 19:16 UTC

Ligand Pharmaceuticals Inc shares are lower today, experiencing volatility amid rising oil prices and inflation concerns ahead of key U.S. inflation data.

10 авг. 2026 г., 21:51 UTC

Ligand Pharmaceuticals Inc shares declined in after-market hours, continuing a downward trend with no specific news to explain the movement.

7 авг. 2026 г., 20:02 UTC

News

Ligand Pharmaceuticals Inc shares are lower despite a strong second-quarter performance, as profit-taking and high trading volume weigh on the stock.

6 авг. 2026 г., 20:03 UTC

News

Ligand Pharmaceuticals Inc reported strong Q2 results, with adjusted EPS of $2.37, exceeding expectations. The company raised its full-year EPS guidance amid sector gains.

5 авг. 2026 г., 19:26 UTC

Ligand Pharmaceuticals Inc shares are higher during Wednesday's session, despite pulling back from earlier gains. Broader market sentiment is supported by declining crude oil prices.

3 авг. 2026 г., 19:36 UTC

News

Oppenheimer raised its price target on Ligand Pharmaceuticals to $326, reinforcing positive investor sentiment as shares trade higher during Monday's session.

31 июл. 2026 г., 23:36 UTC

Ligand Pharmaceuticals Inc shares are lower in after-market trading, influenced by broader market pressure from Apple's weaker guidance. No specific company news was identified.

30 июл. 2026 г., 22:16 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market hours, despite routine trading and no specific news driving the price action.

29 июл. 2026 г., 21:02 UTC

Ligand Pharmaceuticals Inc. shares are higher in after-market hours, despite broader market volatility and a six-session decline leading up to today.

28 июл. 2026 г., 19:22 UTC

Ligand Pharmaceuticals Inc is lower today, continuing a five-session decline, with no specific news driving the movement and unusually high trading volume.

27 июл. 2026 г., 19:26 UTC

News

Ligand Pharmaceuticals Inc. shares are lower today, continuing a four-session decline amid concerns over its recent acquisition of XOMA Royalty Corp.

24 июл. 2026 г., 22:06 UTC

Ligand Pharmaceuticals Inc. shares were little changed in after-market trading, with no specific news identified. Broader market trends showed mixed signals.

23 июл. 2026 г., 21:03 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market trading, following a rise in crude oil prices amid geopolitical tensions, though no specific company news was identified.

21 июл. 2026 г., 20:02 UTC

News

Ligand Pharmaceuticals is higher after Citi resumed coverage with a Buy rating and a price target of $387, citing benefits from the XOMA acquisition.

Сравнение c конкурентами

Изменение цены

Ligand Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

25.23% рост

Прогноз на 12 месяцев

Средняя 350.86 USD 25.23%

Максимум 390 USD

Минимум 326 USD

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Ligand Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

8 ratings

Покупка

Удержание

Продажа

Основано на мнении 8 аналитиков, присваивавших рейтинги акциям Ligand Pharmaceuticals Inc – Данные за последние 3 месяца.

Настроения

By Acuity

136 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.